Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 20/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10240423 | 0.89 | ALOX5AP (0.57) | ALOX5AP | |
| SCHEMBL10240640 | 0.89 | ALOX5AP (0.83) | ALOX5APCYP2D6CYP2C9 | |
| SCHEMBL11973137 | 0.88 | ALOX5AP (0.74) | ALOX5APCYP2D6CYP2C9 | |
| SCHEMBL725038 | 0.88 | ALOX5AP (0.70) | ALOX5APCYP2D6CYP2C9 | |
| SCHEMBL10240754 | 0.88 | ALOX5AP (0.62) | ALOX5APCYP2D6CYP2C9 | |
| SCHEMBL10240688 | 0.87 | ALOX5AP (0.65) | ALOX5APCYP2D6CYP2C9 | |
| SCHEMBL10241345 | 0.87 | ALOX5AP (0.69) | ALOX5APCYP2D6CYP2C9 | |
| SCHEMBL16602821 | 0.85 | ALOX5AP (0.66) | ALOX5APCYP2D6CYP2C9 | |
| SCHEMBL10240534 | 0.84 | ALOX5AP (0.64) | ALOX5APCYP2D6CYP2C9 | |
| SCHEMBL10240725 | 0.84 | ALOX5AP (0.89) | ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2609092-B1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INT (DE) | 2015-04-01 | — | — | EP | disclosed |
| EP-2609092-B1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INT (DE) | 2015-04-01 | — | — | EP | disclosed |
| US-8580829-B2 | Oxadiazole inhibitors of leukotriene production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-12 | — | — | US | disclosed |
| US-8580829-B2 | Oxadiazole inhibitors of leukotriene production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-12 | — | — | US | disclosed |
| US-20120214787-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-23 | — | — | US | disclosed |
| US-20120214787-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-23 | — | — | US | disclosed |
| WO-2012027322-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214787-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | LTB4R, LTC4S, LTB4R2 | ALOX5AP 17/4885CYP2D6 245/4885CYP2C9 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.